Long-term safety of first-line osimertinib plus platinum–pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2

Study limitation reported by the research below: “This is a post-hoc, single-arm safety analysis of the combination group in FLAURA2; no formal statistical comparison to the monotherapy arm is made, limiting causal inference about relative toxicity. Study design tag reflects the post-hoc nature layered on a phase 3 RCT.”